Program/Compound NX-217 Β· EU5 Launch
Phase III

πŸ‡«πŸ‡· France

Drill-down: 5 tasks Β· 1 risks Β· launch 25 May 2026

Status

On track

Readiness

24%

Baseline 5Y

€378.0M

Adjusted 5Y

€378.0M

Plan

Task
Oct 25
Nov 25
Dec 25
Jan 26
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Today
Regulatory
Market Access
Medical
Supply
Marketing
Baseline On track In progress Delayed Gating task

Risks (1)

Medium
Julien Moreau

Reference pricing exposure from German AMNOG outcome β€” CEPS may anchor below target.

Files

Global Launch Playbook v3.2.pdf4.2 MB
Global HCP Campaign Toolkit.zip120.6 MB
Master Messaging Framework v2.1.pdf3.4 MB
Phase III Topline Results β€” NX-217.pdf6.7 MB
EU5 Patient Journey Research.pdf14.2 MB
HAS SMR/ASMR Dossier FR.pdf22.9 MB
Global Brand Visual Identity.zip210.3 MB